CLARITAS PHARMACEUTICALS, INC.

Press Releases Claritas Pharmaceuticals, Inc.

Equities

CLAS.H

CA1806342061

End-of-day quote Toronto S.E. Other stock markets 06:00:00 2022-07-18 pm EDT			5-day change	1st Jan Change
0.025 ^CAD	-16.67%		-.--%	-.--%

2021	Claritas Pharmaceuticals : Updates Proposed Financing with Obsidian, Receives Australian Tax Credit, Starts Phase 1 Study of R-107	MT
2021	Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Claritas Pharmaceuticals : IIROC Trading Resumption - CLAS	21-08-18	AQ
Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax Credit, and Start of Phase 1 Clinical Study of R-107	21-08-18	GL
Claritas Pharmaceuticals : IIROC Trading Halt - CLAS	21-08-18	AQ
Claritas Announces Grant of Stock Options to Directors and Officers	21-07-27	GL
Claritas Pharmaceuticals : Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107	21-07-26	AQ
Claritas Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease	21-07-21	GL
Claritas Announces Effective Date for Share Consolidation	21-07-20	GL
Claritas Pharmaceuticals : Announces Commitments from Company's Largest Shareholders to Vote for Approval of Share Consolidation	21-06-11	AQ
Claritas Announces Commitments from Company’s Largest Shareholders to Vote for Approval of Share Consolidation	21-06-10	GL
Claritas Announces Transfer of GVHD Program and Cancellation of Related Debt as Company Focuses on Nitric Oxide Therapeutics	21-06-01	GL
Claritas Pharmaceuticals : Announces Settlement of Debt Transaction	21-05-31	AQ
Claritas Pharmaceuticals Issues Letter to Shareholders	21-05-11	GL
Claritas Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107	21-04-21	GL
Claritas Announces Letter of Intent to Acquire Exclusive Worldwide Rights to Develop R-107 for PAH	21-04-14	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW